These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 19793506)
1. New therapies for diabesity. Bailey CJ Curr Diab Rep; 2009 Oct; 9(5):360-7. PubMed ID: 19793506 [TBL] [Abstract][Full Text] [Related]
2. How to fight obesity with antidiabetic drugs: targeting gut or kidney? Baretić M; Troskot R Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984 [TBL] [Abstract][Full Text] [Related]
3. The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus. Munir KM; Davis SN Expert Opin Pharmacother; 2015; 16(15):2331-41. PubMed ID: 26340427 [TBL] [Abstract][Full Text] [Related]
5. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Gallwitz B Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience. Deol H; Lekkakou L; Viswanath AK; Pappachan JM Endocrine; 2017 Jan; 55(1):173-178. PubMed ID: 27696231 [TBL] [Abstract][Full Text] [Related]
7. [GLP-1 receptor agonists versus SGLT-2 inhibitors in obese type 2 diabetes patients]. Marques AR; Jaafar J; de Kalbermatten B; Philippe J Rev Med Suisse; 2015 Jun; 11(477):1227-8, 1230-3. PubMed ID: 26211282 [TBL] [Abstract][Full Text] [Related]
8. Treating Diabetes in Patients with Heart Failure: Moving from Risk to Benefit. DeFilippis EM; Givertz MM Curr Heart Fail Rep; 2016 Jun; 13(3):111-8. PubMed ID: 27188181 [TBL] [Abstract][Full Text] [Related]
9. Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. Triplitt C; Solis-Herrera C; Cersosimo E; Abdul-Ghani M; Defronzo RA Expert Opin Pharmacother; 2015; 16(18):2819-33. PubMed ID: 26583910 [TBL] [Abstract][Full Text] [Related]
10. Peptide-based GLP-1/glucagon co-agonists: A double-edged sword to combat diabesity. Soni H Med Hypotheses; 2016 Oct; 95():5-9. PubMed ID: 27692167 [TBL] [Abstract][Full Text] [Related]
11. [Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)]. Gallwitz B MMW Fortschr Med; 2010 May; 152(20):43-4. PubMed ID: 20552881 [No Abstract] [Full Text] [Related]
12. [New pharmacological treatment methods of type 2 diabetes]. Madsbad S; Hermansen K Ugeskr Laeger; 2012 Sep; 174(37):2143-6. PubMed ID: 22971293 [TBL] [Abstract][Full Text] [Related]
13. Management of type 2 diabetes: new and future developments in treatment. Tahrani AA; Bailey CJ; Del Prato S; Barnett AH Lancet; 2011 Jul; 378(9786):182-97. PubMed ID: 21705062 [TBL] [Abstract][Full Text] [Related]
15. Clinical use of GLP-1 agonists and DPP4 inhibitors. Tuch BE Pancreatology; 2016; 16(1):8-9. PubMed ID: 26138513 [TBL] [Abstract][Full Text] [Related]
16. Insulin resistance: Impact on therapeutic developments in diabetes. Bailey CJ Diab Vasc Dis Res; 2019 Mar; 16(2):128-132. PubMed ID: 31014100 [TBL] [Abstract][Full Text] [Related]
17. [Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes]. Álvarez-Guisasola F; Orozco-Beltrán D; Cebrián-Cuenca AM; Ruiz Quintero MA; Angullo Martínez E; Ávila Lachica L; Ortega Millán C; Caride Miana E; Navarro-Pérez J; Sagredo Perez J; Barrot de la Puente J; Cos Claramunt FX Aten Primaria; 2019; 51(7):442-451. PubMed ID: 31320123 [TBL] [Abstract][Full Text] [Related]
18. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Gilbert MP; Pratley RE Front Endocrinol (Lausanne); 2020; 11():178. PubMed ID: 32308645 [TBL] [Abstract][Full Text] [Related]
19. Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Lorenz M; Evers A; Wagner M Bioorg Med Chem Lett; 2013 Jul; 23(14):4011-8. PubMed ID: 23743288 [TBL] [Abstract][Full Text] [Related]
20. A Review on the Effects of New Anti-Diabetic Drugs on Platelet Function. Yaribeygi H; Atkin SL; Jamialahmadi T; Sahebkar A Endocr Metab Immune Disord Drug Targets; 2020; 20(3):328-334. PubMed ID: 31612835 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]